Literature DB >> 3841026

Amsacrine with high-dose cytarabine in acute leukemia.

R Zittoun, J Bury, P Stryckmans, B Lowenberg, M Peetermans, K Y Rozendaal, C Haanen, M Kerkhofs, U Jehn, R Willemze.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3841026

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  5 in total

1.  Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime.

Authors:  R Liang; T K Chan; D Todd
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine.

Authors:  J Mirro; D K Kalwinsky; H E Grier; V M Santana; C Mason; S B Murphy; G V Dahl
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment.

Authors:  W Hiddemann; T Büchner
Journal:  Blut       Date:  1990-03

4.  High-dose ara-C and etoposide in refractory or relapsing acute leukemia.

Authors:  M Freund; H Link; H Diedrich; S LeBlanc; H J Wilke; H Poliwoda
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Five-day 4'-(9-acridinylamino)methanesulphon-m-anisidide and intermediate-dose cytosine arabinoside in high-risk relapsing or refractory acute myeloid leukemia.

Authors:  M Freund; S Giller; F Hinrichs; A Baars; J Meran; A Körfer; H Link; H Poliwoda
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.